Jagsonpal Pharma Q1FY27 Unaudited Results: Revenue at ₹82.23 Cr, Profit ₹17.68 Cr
Jagsonpal Pharmaceuticals reported unaudited standalone results for Q1FY27. Revenue was ₹82.23 crore and profit ₹13.19 crore. The company acquired an 85% stake in Aequitas Healthcare for ₹20.8 crore and completed a ₹40 crore buyback. A dividend of ₹4 per share was recommended.
The results are positive, and the acquisition and buyback are material events for the company, suggesting a medium impact on its future performance and shareholder value.
The company reported positive financial results with increased revenue and profit compared to the previous year's comparable quarter. The acquisition and buyback further indicate strategic business activities.
Jagsonpal Pharmaceuticals Limited announced its unaudited standalone financial results for the quarter ended June 30, 2026. The company reported a total income of ₹850.65 million (₹85.07 crore) for the quarter, with revenue from operations standing at ₹822.32 million (₹82.23 crore) and other income at ₹28.33 million (₹2.83 crore).
Total expenses for the quarter were ₹673.85 million (₹67.39 crore). The profit before exceptional items and tax stood at ₹176.80 million (₹17.68 crore), and the net profit for the period was ₹131.89 million (₹13.19 crore). Basic earnings per share were ₹2.00, and diluted earnings per share were ₹1.98.
The Board of Directors met on July 29, 2026, from 03:45 p.m. to 04:17 p.m. to approve these financial results. The company also noted that during the quarter, it entered into a Share Purchase Agreement on June 29, 2026, to acquire an 85% equity stake in Aequitas Healthcare Private Limited for a consideration of ₹208 million (₹20.8 crore), to be funded through internal accruals. The transfer of shares and completion of closing formalities were subsequently completed in July 2026.
Additionally, the company granted 153,000 stock options under its Employee Stock Option Plan 2022 and allotted 473,220 equity shares on the exercise of vested stock options. A final dividend of ₹4 per equity share for the year ended March 31, 2026, was recommended, subject to approval at the Annual General Meeting. The company also completed a buy-back of up to 1,600,000 equity shares at ₹250 per share for an aggregate consideration not exceeding ₹400 million (₹40 crore) during the quarter.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.